MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
MapLight Therapeutics, Inc.NASDAQ: MPLT
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$60.51M, compared with -$22.17M a year earlier. Trailing-twelve-month EBITDA was -$198.91M.
Context
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -108.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$60.51M+23.8% QoQ
- Last fiscal yearDec 2025
- -$160.57M-108.9% YoY
- LTMMar 2026
- -$198.91M-147.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -172.9% | +100.0% | +272.9 pp |
| 1 year | -108.9% | +100.0% | +208.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (160.57M) USD
- Year-over-year change
- -108.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (160.57M) | -108.9% |
| FY2024 | 2024-12-31 | (76.88M) | -39.4% |
| FY2023 | 2023-12-31 | (55.15M) | -87.3% |
| FY2022 | 2022-12-31 | (29.44M) | — |
EBITDA vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's LTM Mar 2026 EBITDA of -$198.91M is the 8th highest of the 11 companies compared; the peer median is -$63.57M.
- Its year-over-year change of -147.8% is the 9th highest of 10, against a peer median of -16.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $140.47M | +332.9% | — | 114.9% | |
| LTM Mar 2026 | -$24M | +7.8% | — | 337.0% | |
| LTM Dec 2025 | -$38.87M | +24.6% | — | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | -$39.05M | — | — | — |
| LTM Mar 2026 | -$55.86M | -33.8% | — | — | |
| LTM Mar 2026 | -$71.29M | -16.9% | — | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$118.15M | -28.2% | — | 590.7% |
| LTM Mar 2026 | -$198.91M | -147.8% | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$217.64M | +15.4% | — | — |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | -$323.53M | -99.1% | — | — |
| LTM Jun 2026 | -$394.35M | -3608.6% | — | — | |
| Peer median (excluding MPLT) | -$63.57M | -16.9% | — | 337.0% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 574K | 556K | 701K | 578K |
| Gross Profit | (574K) | (556K) | (701K) | (578K) |
| Gross Margin | — | — | — | — |
| Research & Development | 26.57M | 49.12M | 67.82M | 137.77M |
| Selling, General & Admin | 4.1M | 7.61M | 14.42M | 30.73M |
| Operating Expenses | 30.67M | 56.73M | 82.25M | 168.51M |
| Depreciation & Amortization | 574K | 556K | 701K | 578K |
| EBITDA | (29.44M) | (55.15M) | (76.88M) | (160.57M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (31.25M) | (57.28M) | (82.95M) | (169.08M) |
| Operating Margin | — | — | — | — |
| Interest Income | 429K | 1.1M | 4.5M | 5.52M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.23M | 1.57M | 5.37M | 7.93M |
| Income Before Tax | (30.02M) | (55.71M) | (77.58M) | (161.15M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (30.02M) | (55.71M) | (77.58M) | (161.15M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.72) | (1.34) | (1.87) | (3.66) |
| EPS (Diluted) | (0.72) | (1.34) | (1.87) | (3.66) |
| Weighted Avg Shares | 41.43M | 41.43M | 41.43M | 44.02M |
| Weighted Avg Shares (Diluted) | 41.43M | 41.43M | 41.43M | 44.02M |
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.